Covid-19 Vaccine Updates: The British government on Friday formally asked the drug regulator to approve the use of the Corona vaccine prepared by AstraZeneca and Oxford University. The British government’s move comes at a time when vaccine manufacturers have acknowledged that the better results of vaccine testing have been the result of dose errors (giving one shot instead of two). According to the Chief Executive of AstraZeneca, the vaccine will now be tested globally with low doses. Amidst all this, the developers of the Russian vaccine Sputnik 5 have told AstraZeneca that they should test their experimental shot by mixing it with Russian shot to increase the vaccine’s effect (affixi).
According to claims, Sputnik vaccine is up to 92% effective in prevention of corona infection, while AstraZeneca says that its vaccine is up to 70% effective which can be up to 90% effective.
Clinical trial will be done with single dose
According to a Bloomberg News report, Pascal Soriot, chief executive of AstraZeneca, has said that the company may soon test its vaccine with lower doses which have given better full doses (two shots). The clinical trial of vaccine continues in the US. He said that now his effort is to validate the result of low doses. However, he believes that this international study will take less time because it is more effective at low doses, so fewer patients will be needed.
Recommend amendment by taking license for two shots
According to British Health Secretary Matt Hancock, information has been sought from the Medicines and Healthcare Products Regulatory (MHRA) on whether the vaccine has met safety standards. The regulator has said that it cannot say for approval how much time it may take to approve the vaccine. MHRA Chief Executive June Rayne said that the vaccine would be approved only if the standards were met. Helen Fletcher, a professor of immunology at the London School of Hygiene and Tropical Medicine, says the British vaccine can take a license for high doses (two shots) and then immediately seek amendments for the use of low doses. However, they should have enough data for this.
Britain has done 100 million dose orders
Oxford and AstraZeneca found in the clinical trial of the vaccine that it was 62% effective on those given two doses and 90% effective on those given one dose. The British government has ordered 100 million doses of Oxford-AstraZeneca and plans to distribute it by the end of this year if approved.
Cheaper and Affordable than Other Vaccines
The vaccine produced by AstraZeneca and Oxford University is waiting longer because it does not need to be kept at a cool temperature like the vaccine produced by Pfizer and Moderna. Because of this, it will be easy to distribute, especially in developing countries. Apart from this, it will also be cheaper because the company has said that it will not make profit from it at the time of the epidemic.
Single dose trial by mistake
Soriot says it may take longer to get approval for this vaccine from the US regulatory FDA because this agency may refuse to approve a vaccine study anywhere other than the US. AstraZeneca’s research chief, Maine Panglos, told Routers a few days ago that some volunteers were accidentally given fewer doses during the clinical trial of the Corona vaccine. They believe that it was not part of the experiment.